PI-RADS version 2.1 demonstrated improved detection of clinically significant prostate cancer in the transition zone. For detecting clinically significant prostate cancer (csPCa), prostate imaging ...

An artificial intelligence system slightly outperformed radiologists using PI-RADS at detecting clinically significant prostate cancer. A trained artificial intelligence (AI) system discriminated ...

Prostate MRI currently lacks the accuracy to replace biopsies in active surveillance for prostate cancer. The negative predictive value of MRI remains below 90%, the general goal for safely avoiding ...

When MRI offered no clear answer in suspected prostate cancer, the use of prostate-specific membrane antigen (PSMA)-PET/CT showed promise for reducing the number of biopsies without compromising the ...

In a cohort of US veterans with prostate cancer who were on active surveillance, negative multiparametric MRI had a 75% negative predictive value for ruling out disease of grade group 2 or higher at ...

Prostate cancer surgeons routinely use MRI to guide surgical planning, yet imaging findings are not used for risk stratification in standard prognostic models. A new meta-analysis suggests they should ...

AI-driven MRI analysis offers new insights into prostate cancer prognosis, accurately predicting metastasis risk and treatment outcomes for improved patient care. Study: AI-derived Tumor Volume from ...

DEAR DR. ROACH: I am 77 years old, and I’m concerned about getting a prostate biopsy. My last PSA test jumped from 2.25 to 3.75 ng/mL, and an MRI came back healthy and normal with a PI-RADS code of 2.

Basal-luminal classifiers, such as PAM50, may predict prostate cancer grade progression risk in men with low- to intermediate-risk prostate cancer who are considering active surveillance.